Drug Profile
Research programme: cell permeable peptide therapies - Portage Biotech
Alternative Names: Cell permeable peptide fusion proteins- Portage PharmaceuticalsLatest Information Update: 29 Mar 2023
Price :
$50
*
At a glance
- Originator Portage Biotech
- Class Conjugate vaccines; Nucleotides; Peptide vaccines; Recombinant fusion proteins
- Mechanism of Action NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Eye disorders; Neurological disorders
Most Recent Events
- 29 Mar 2023 Discontinued - Preclinical for Eye disorders in USA (Ophthalmic) (Portage Biotech pipeline, March 2023)
- 29 Mar 2023 Discontinued - Preclinical for Neurological disorders in USA (unspecified route) (Portage Biotech pipeline, March 2023)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Eye-disorders in USA (Ophthalmic, Drops)